AU2022271243A1 - Combination therapies comprising shp2 inhibitors and pd-1 inhibitors - Google Patents

Combination therapies comprising shp2 inhibitors and pd-1 inhibitors Download PDF

Info

Publication number
AU2022271243A1
AU2022271243A1 AU2022271243A AU2022271243A AU2022271243A1 AU 2022271243 A1 AU2022271243 A1 AU 2022271243A1 AU 2022271243 A AU2022271243 A AU 2022271243A AU 2022271243 A AU2022271243 A AU 2022271243A AU 2022271243 A1 AU2022271243 A1 AU 2022271243A1
Authority
AU
Australia
Prior art keywords
inhibitor
cancer
compound
patient
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022271243A
Other languages
English (en)
Inventor
Mireille GILLINGS
Robert Goodenow
Jill M. RICONO
Farbod Shojaei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huyabio International LLC
Original Assignee
Huyabio International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio International LLC filed Critical Huyabio International LLC
Publication of AU2022271243A1 publication Critical patent/AU2022271243A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022271243A 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and pd-1 inhibitors Pending AU2022271243A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163184685P 2021-05-05 2021-05-05
US63/184,685 2021-05-05
US202263320997P 2022-03-17 2022-03-17
US63/320,997 2022-03-17
PCT/US2022/027696 WO2022235817A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Publications (1)

Publication Number Publication Date
AU2022271243A1 true AU2022271243A1 (en) 2023-11-30

Family

ID=83932910

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022271243A Pending AU2022271243A1 (en) 2021-05-05 2022-05-04 Combination therapies comprising shp2 inhibitors and pd-1 inhibitors

Country Status (8)

Country Link
US (1) US12097203B2 (https=)
EP (1) EP4334318A4 (https=)
JP (1) JP2024516037A (https=)
AU (1) AU2022271243A1 (https=)
CA (1) CA3217084A1 (https=)
IL (1) IL308222A (https=)
MX (1) MX2023013064A (https=)
WO (1) WO2022235817A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023012929A (es) * 2021-05-05 2023-11-13 Huyabio Int Llc Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr.
AU2023385809A1 (en) * 2022-11-23 2025-05-29 Huyabio International, Llc Combination therapies comprising KRAS inhibitors and SHP2 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
MX388576B (es) 2016-06-07 2025-03-20 Jacobio Pharmaceuticals Co Ltd Derivados heterociclicos novedosos utiles como inhibidores de shp2.
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP4302834A3 (en) 2016-07-12 2024-07-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
EA202190196A1 (ru) 2017-03-23 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CA3074690A1 (en) 2017-09-07 2019-03-14 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
US11110171B2 (en) * 2017-12-21 2021-09-07 New York University PD-1 related cancer therapy
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
RU2020133727A (ru) 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
MX2020010719A (es) 2018-04-10 2020-11-06 Revolution Medicines Inc Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2.
JP2022508651A (ja) * 2018-10-08 2022-01-19 レヴォリューション・メディスンズ，インコーポレイテッド 癌を処置するためのｓｈｐ２阻害剤組成物および方法
MX2021009562A (es) 2019-02-12 2021-09-08 Novartis Ag Combinacion farmaceutica que comprende tno155 y un inhibidor de pd-1.
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
CN114502165A (zh) 2019-09-23 2022-05-13 苏州浦合医药科技有限公司 Shp2抑制剂及其用途

Also Published As

Publication number Publication date
US12097203B2 (en) 2024-09-24
US20220370457A1 (en) 2022-11-24
MX2023013064A (es) 2023-11-15
EP4334318A1 (en) 2024-03-13
IL308222A (en) 2024-01-01
JP2024516037A (ja) 2024-04-11
WO2022235817A1 (en) 2022-11-10
EP4334318A4 (en) 2025-03-05
CA3217084A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
US12390469B2 (en) SHP2 inhibitor monotherapy and uses thereof
US20100104567A1 (en) Pharmaceutical composition
KR101950520B1 (ko) 푸코스 유사체를 사용한 생체 내에서의 단백질 푸코실화 억제 방법
EP4434549A1 (en) Antibody-drug conjugate and use thereof
EP3673907A1 (en) Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
WO2017146236A1 (ja) Ａｘｌ阻害剤と免疫チェックポイント阻害剤とを組み合わせて投与することを特徴とする癌治療のための医薬
EA032509B1 (ru) Замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
KR20140045288A (ko) 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
CN116472045B (zh) 使用杂芳基联苯基酰胺衍生物治疗癌症的方法
US12097203B2 (en) Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
WO2022092085A1 (ja) 腫瘍治療用医薬組成物
CN117677619A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
US20220370456A1 (en) Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors
HK40108828A (zh) 包含shp2抑制剂和pd-1抑制剂的联合疗法
CN117642398A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
WO2023034530A1 (en) Methods of improving growth and function of immune cells
HK40108830A (zh) 包含shp2抑制剂和egfr酪氨酸激酶抑制剂的联合疗法
US20230097801A1 (en) Methods of increasing cell phagocytosis
HK40108829A (zh) Shp2抑制剂单一疗法及其用途
WO2023057882A1 (en) Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer
HK40013795A (en) Combination of immunotherapies with mdm2 inhibitors